Find My Journal

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara

The Lancet, 2016

Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Samsung Medical Center, Sungkyunkwan University, University of Naples Federico II, Asklepios Fachkliniken München-Gauting, The Barbara Ann Karmanos Cancer Institute, Wayne State University, Aichi Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Regional Universitario de Málaga, Azienda Ospedaliera San Gerardo, Minnesota Oncology, Pontifícia Universidade Católica do Rio Grande do Sul, University of California, Los Angeles, Centro de Estudios Científicos, European Institute of Oncology, Istanbul University, Istanbul University-Cerrahpaşa, Seoul National University Bundang Hospital, University of California, Davis, UC Davis Comprehensive Cancer Center

View Free PDF Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

4738

Citations

View on Google Scholar